Ameya Kirtane

Ameya Kirtane

Harvard University

H-index: 23

North America-United States

About Ameya Kirtane

Ameya Kirtane, With an exceptional h-index of 23 and a recent h-index of 21 (since 2020), a distinguished researcher at Harvard University, specializes in the field of Drug delivery.

His recent articles reflect a diverse array of research interests and contributions to the field:

Screening oral drugs for their interactions with the intestinal transportome via porcine tissue explants and machine learning

Closed-loop automated drug infusion regulator: A clinically translatable, closed-loop drug delivery system for personalized drug dosing

A multifunctional decellularized gut suture platform

Challenges and opportunities in the development of mucosal mRNA vaccines

Oleogel and oleopaste compositions and uses thereof

Physical methods to overcome tissue barriers in vaccine delivery

Profiling of Circulating Tumor Cells for Screening of Selective Inhibitors of Tumor‐Initiating Stem‐Like Cells

Enzyme‐Triggered Intestine‐Specific Targeting Adhesive Platform for Universal Oral Drug Delivery (Adv. Healthcare Mater. 27/2023)

Ameya Kirtane Information

University

Harvard University

Position

Brigham and Women's Hospital, Harvard Medical School

Citations(all)

2076

Citations(since 2020)

1607

Cited By

967

hIndex(all)

23

hIndex(since 2020)

21

i10Index(all)

33

i10Index(since 2020)

30

Email

University Profile Page

Harvard University

Ameya Kirtane Skills & Research Interests

Drug delivery

Top articles of Ameya Kirtane

Screening oral drugs for their interactions with the intestinal transportome via porcine tissue explants and machine learning

Authors

Yunhua Shi,Daniel Reker,James D Byrne,Ameya R Kirtane,Kaitlyn Hess,Zhuyi Wang,Natsuda Navamajiti,Cameron C Young,Zachary Fralish,Zilu Zhang,Aaron Lopes,Vance Soares,Jacob Wainer,Thomas von Erlach,Lei Miao,Robert Langer,Giovanni Traverso

Journal

Nature biomedical engineering

Published Date

2024/2/20

In vitro systems that accurately model in vivo conditions in the gastrointestinal tract may aid the development of oral drugs with greater bioavailability. Here we show that the interaction profiles between drugs and intestinal drug transporters can be obtained by modulating transporter expression in intact porcine tissue explants via the ultrasound-mediated delivery of small interfering RNAs and that the interaction profiles can be classified via a random forest model trained on the drug–transporter relationships. For 24 drugs with well-characterized drug–transporter interactions, the model achieved 100% concordance. For 28 clinical drugs and 22 investigational drugs, the model identified 58 unknown drug–transporter interactions, 7 of which (out of 8 tested) corresponded to drug-pharmacokinetic measurements in mice. We also validated the model’s predictions for interactions between doxycycline and four drugs …

Closed-loop automated drug infusion regulator: A clinically translatable, closed-loop drug delivery system for personalized drug dosing

Authors

Louis B DeRidder,Kyle A Hare,Aaron Lopes,Josh Jenkins,Nina Fitzgerald,Emmeline MacPherson,Niora Fabian,Josh Morimoto,Jacqueline N Chu,Ameya R Kirtane,Wiam Madani,Keiko Ishida,Johannes LP Kuosmanen,Naomi Zecharias,Christopher M Colangelo,Hen-Wei Huang,Makaya Chilekwa,Nikhil B Lal,Shriya S Srinivasan,Alison M Hayward,Brian M Wolpin,David Trumper,Troy Quast,Douglas A Rubinson,Robert Langer,Giovanni Traverso

Journal

Med

Published Date

2024/4/24

BackgroundDosing of chemotherapies is often calculated according to the weight and/or height of the patient or equations derived from these, such as body surface area (BSA). Such calculations fail to capture intra- and interindividual pharmacokinetic variation, which can lead to order of magnitude variations in systemic chemotherapy levels and thus under- or overdosing of patients.MethodsWe designed and developed a closed-loop drug delivery system that can dynamically adjust its infusion rate to the patient to reach and maintain the drug's target concentration, regardless of a patient's pharmacokinetics (PK).FindingsWe demonstrate that closed-loop automated drug infusion regulator (CLAUDIA) can control the concentration of 5-fluorouracil (5-FU) in rabbits according to a range of concentration-time profiles (which could be useful in chronomodulated chemotherapy) and over a range of PK conditions that …

A multifunctional decellularized gut suture platform

Authors

Jung Seung Lee,Hyunjoon Kim,Gwennyth Carroll,Gary W Liu,Ameya R Kirtane,Alison Hayward,Adam Wentworth,Aaron Lopes,Joy Collins,Siid Tamang,Keiko Ishida,Kaitlyn Hess,Junwei Li,Sufeng Zhang,Giovanni Traverso

Journal

Matter

Published Date

2023/7/5

Wound closure is critical for the care of wounds by preventing foreign matter entry and supporting healing. Failure of wound closure because of mechanical compromise or inflammation can lead to failure of effective apposition of tissues and manifest in delayed healing and even death, depending on the site of the wound. Therefore, a platform capable of identifying inflammation as well as delivery of therapeutics, including chemical, biological, and cellular therapies, could transform our capacity to effectively sense potential failure as well as maximize healing. Here, we report the development of a decellularized gut suture platform capable of sensing inflammation as well as delivering a broad array of therapeutics, including small molecules, monoclonal antibodies, and cell-based therapeutics. We demonstrate the mechanical and biological functionalities of our platform in rodents and pigs. We anticipate that this …

Challenges and opportunities in the development of mucosal mRNA vaccines

Authors

Séverine Ravez,Quentin Spillier,Romain Marteau,Olivier Feron,Raphaël Frédérick

Published Date

2017/2/23

Recent advances in the understanding of the relationship between cancer and metabolism have highlighted the relevance of the serine synthetic pathway (SSP), which consists of three successive enzymatic reactions. Enzymes of the SSP, such as phosphoglycerate dehydrogenase (PHGDH) and phosphoserine aminotransferase 1 (PSAT-1), were recently highlighted because they are amplified in a significant subset of human tumors, and their suppression by RNAi caused a decrease in cancer cell survival and growth. Currently, the discovery of drugs that inhibit these enzymes is still in its infancy, and the identification of suitable inhibitors could serve to understand the emerging biology of these metabolic enzymes. In this review, we present the SSP as a significant and novel emerging area for medicinal chemistry and we provide an overview of one of the key enzymes of the pathway, PHGDH.

Oleogel and oleopaste compositions and uses thereof

Published Date

2023/6/15

The present disclosure provides oleogel and oleopaste compositions, as well as methods, kits, preparations, and methods of using the same. The oleogels and oleopastes presented herein include compositions comprising azithromycin, albendazole, lumefantrine, praziquantel, moxifloxacin, and ivermectin.

Physical methods to overcome tissue barriers in vaccine delivery

Authors

Taksim Ahmed,Dylan Freitas,Xisha Huang,Qing Rui Simon Qu,Giovanni Traverso,Ameya Kirtane

Journal

Vaccine Insights

Published Date

2023/10/25

Vaccination represents one of the oldest and most effective public health interventions. Vaccines are routinely administered via systemic injections. Due to the invasive nature of this technique, it introduces several challenges. Vaccine administration without the use of needles would be beneficial. However, vaccine uptake is significantly limited by the presence of tissue barriers. Here, we review physical methods that disrupt these tissue barriers and enable efficient vaccine delivery. Four methods, namely microneedles, needle-free jet injectors, electroporation, and ultrasound. We focus on how these methods compare to needle-based vaccination in preclinical and clinical studies, and discuss their use in mucosal vaccination. In sum, these methods offer an attractive alternative to conventional vaccine delivery strategies; however, much work needs to be done to further improve their efficacy.

Profiling of Circulating Tumor Cells for Screening of Selective Inhibitors of Tumor‐Initiating Stem‐Like Cells

Authors

Chia‐Lin Chen,Juan Carlos Hernandez,Dinesh Babu Uthaya Kumar,Tatsuya Machida,Stanley M Tahara,Anthony El‐Khoueiry,Meng Li,Vasu Punj,Suresh Kumar Swaminathan,Ameya Kirtane,Yibu Chen,Jayanth Panyam,Keigo Machida

Journal

Advanced Science

Published Date

2023/5

A critical barrier to effective cancer therapy is the improvement of drug selectivity, toxicity, and reduced recurrence of tumors expanded from tumor‐initiating stem‐like cells (TICs). The aim is to identify circulating tumor cell (CTC)‐biomarkers and to identify an effective combination of TIC‐specific, repurposed federal drug administration (FDA)‐approved drugs. Three different types of high‐throughput screens targeting the TIC population are employed: these include a CD133 (+) cell viability screen, a NANOG expression screen, and a drug combination screen. When combined in a refined secondary screening approach that targets Nanog expression with the same FDA‐approved drug library, histone deacetylase (HDAC) inhibitor(s) combined with all‐trans retinoic acid (ATRA) demonstrate the highest efficacy for inhibition of TIC growth in vitro and in vivo. Addition of immune checkpoint inhibitor further decreases …

Enzyme‐Triggered Intestine‐Specific Targeting Adhesive Platform for Universal Oral Drug Delivery (Adv. Healthcare Mater. 27/2023)

Authors

Ying Li,Jung Seung Lee,Ameya R Kirtane,Mengyuan Li,Charles William Coffey III,Kaitlyn Hess,Aaron Lopes,Joy Collins,Siddartha Tamang,Keiko Ishida,Alison Hayward,Jacob Wainer,Adam J Wentworth,Giovanni Traverso

Journal

Advanced Healthcare Materials

Published Date

2023/10

In article 2301033, Giovanni Traverso and co-workers develop an oral sandwiched pill with in situ gelling systems gelled based on enzyme catalyzed crosslinking reactions, which undergo mild conditions, tunable gelation rate, and tough mechanical properties by a simple mixing to deliver clinically-relevant doses of hydrophilic and hydrophobic drugs in a large animal model, with a sustained half life and T max compared to conventional pills. This work is seen as a transformative step in drug delivery research that ushers in a new era of oral sustained drug delivery: The invention can not only be used to orally deliver drugs to optimize drugs pharmacokinetics after oral administration, but also can be used in gastrointestinal (GI) diagnoses application to ensure the diagnostic device stays in the GI tract for enough time.

Synthetic tissue barriers and uses thereof

Published Date

2023/3/30

The present disclosure provides compositions, methods, and kits that enable the in situ growth of polymers on or within a subject. In some aspects, the tissue-active monomers, including monomers comprising macromolecules, provide abroad set of material choices for synthetic tissue barriers. In additional aspects, the compositions, methods, and kits are useful for treating or preventing a disease or disorder.

Gastrointestinal Delivery of an mRNA Vaccine Using Immunostimulatory Polymeric Nanoparticles

Authors

Hyunjoon Kim,Ameya R Kirtane,Na Yoon Kim,Netra Unni Rajesh,Chaoyang Tang,Keiko Ishida,Alison M Hayward,Robert Langer,Giovanni Traverso

Journal

The AAPS journal

Published Date

2023/8/17

mRNA vaccines can be translated into protein antigens, in vivo, to effectively induce humoral and cellular immunity against these proteins. While current mRNA vaccines have generated potent immune responses, the need for ultracold storage conditions (− 80 °C) and healthcare professionals to administer the vaccine through the parenteral route has somewhat limited their distribution in rural areas and developing countries. Overcoming these challenges stands to transform future deployment of mRNA vaccines. In this study, we developed an mRNA vaccine that can trigger a systemic immune response through administration via the gastrointestinal (GI) tract and is stable at 4 °C. A library of cationic branched poly(β-amino ester) (PBAE) polymers was synthesized and characterized, from which a polymer with high intracellular mRNA delivery efficiency and immune stimulation capacity was down-selected. mRNA …

Poly (Beta-Thioester) Polymers and Polymeric Nanoparticles

Published Date

2022/6/9

The disclosure describes poly (β-thioester) polymers and polymeric nanoparticles, pharmaceutical compositions comprising these materials, their use in the treatment of cancer and infectious disease, and machine learning methods for identifying and selecting them.

Development of oil-based gels as versatile drug delivery systems for pediatric applications

Authors

Ameya R Kirtane,Christina Karavasili,Aniket Wahane,Dylan Freitas,Katelyn Booz,Dao Thi Hong Le,Tiffany Hua,Stephen Scala,Aaron Lopes,Kaitlyn Hess,Joy Collins,Siddartha Tamang,Keiko Ishida,Johannes LP Kuosmanen,Netra Unni Rajesh,Nhi V Phan,Junwei Li,Annlyse Krogmann,Jochen K Lennerz,Alison Hayward,Robert Langer,Giovanni Traverso

Journal

Science Advances

Published Date

2022/5/27

Administering medicines to 0- to 5-year-old children in a resource-limited environment requires dosage forms that circumvent swallowing solids, avoid on-field reconstitution, and are thermostable, cheap, versatile, and taste masking. We present a strategy that stands to solve this multifaceted problem. As many drugs lack adequate water solubility, our formulations used oils, whose textures could be modified with gelling agents to form “oleogels.” In a clinical study, we showed that the oleogels can be formulated to be as fluid as thickened beverages and as stiff as yogurt puddings. In swine, oleogels could deliver four drugs ranging three orders of magnitude in their water solubilities and two orders of magnitude in their partition coefficients. Oleogels could be stabilized at 40°C for prolonged durations and used without redispersion. Last, we developed a macrofluidic system enabling fixed and metered dosing. We …

Oral mRNA delivery using capsule-mediated gastrointestinal tissue injections

Authors

Alex Abramson,Ameya R Kirtane,Yunhua Shi,Grace Zhong,Joy E Collins,Siddartha Tamang,Keiko Ishida,Alison Hayward,Jacob Wainer,Netra Unni Rajesh,Xiaoya Lu,Yuan Gao,Paramesh Karandikar,Chaoyang Tang,Aaron Lopes,Aniket Wahane,Daniel Reker,Morten Revsgaard Frederiksen,Brian Jensen,Robert Langer,Giovanni Traverso

Journal

Matter

Published Date

2022/3/2

Nucleic acids are enabling a new generation of therapeutics and vaccines to treat and prevent a range of diseases. While these therapies have typically been limited to parenteral dosing, patients and clinicians prefer oral dosage forms. Furthermore, oral delivery enables local transfection of cells in the gastrointestinal tract not easily targeted via parenteral administration. To address these challenges, we synthesized and screened a library of branched hybrid poly(β-amino ester) mRNA nanoparticles for transfection efficiency; then we combined the highest performing formulations with ingestible milli-injector capsules capable of delivering formulations directly into gastric tissue. We validated the performance of formulations and devices in rodents and pigs, demonstrating protein translation in the delta, gastric, and parietal cells of the gastric mucosa, in addition to systemic uptake. We anticipate oral delivery of mRNA …

Branched poly (-amino esters) for the delivery of nucleic acids

Published Date

2022/9/15

HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C= C2C [C@@ H](O) CC [C@] 2 (C)[C@@ H] 2 [C@@ H] 1 [C@@ H] 1CC [C@ H]([C@ H](C) CCCC (C) C)[C@@] 1 (C) CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 27

Tissue catalyzed growth of polymer as epithelial linings for therapy

Published Date

2021/6/17

The present disclosure provides compositions, methods, and kits that enable the in situ growth of polymers on or within a subject. In some aspects, the monomer, dopamine, polymerizes in vivo to form a polymer on a tissue. In additional aspects, the compositions, methods, and kits are useful for treating or preventing a disease or disorder.

Personalized radiation attenuating materials for gastrointestinal mucosal protection

Authors

James D Byrne,Cameron C Young,Jacqueline N Chu,Jennifer Pursley,Mu Xian Chen,Adam J Wentworth,Annie Feng,Ameya R Kirtane,Kyla A Remillard,Cindy I Hancox,Mandar S Bhagwat,Nicole Machado,Tiffany Hua,Siddartha M Tamang,Joy E Collins,Keiko Ishida,Alison Hayward,Sarah L Becker,Samantha K Edgington,Jonathan D Schoenfeld,William R Jeck,Chin Hur,Giovanni Traverso

Journal

Advanced Science

Published Date

2021/6

Cancer patients undergoing therapeutic radiation routinely develop injury of the adjacent gastrointestinal (GI) tract mucosa due to treatment. To reduce radiation dose to critical GI structures including the rectum and oral mucosa, 3D‐printed GI radioprotective devices composed of high‐Z materials are generated from patient CT scans. In a radiation proctitis rat model, a significant reduction in crypt injury is demonstrated with the device compared to without (p < 0.0087). Optimal device placement for radiation attenuation is further confirmed in a swine model. Dosimetric modeling in oral cavity cancer patients demonstrates a 30% radiation dose reduction to the normal buccal mucosa and a 15.2% dose reduction in the rectum for prostate cancer patients with the radioprotectant material in place compared to without. Finally, it is found that the rectal radioprotectant device is more cost‐effective compared to a hydrogel …

Computationally guided high-throughput design of self-assembling drug nanoparticles

Authors

Daniel Reker,Yulia Rybakova,Ameya R Kirtane,Ruonan Cao,Jee Won Yang,Natsuda Navamajiti,Apolonia Gardner,Rosanna M Zhang,Tina Esfandiary,Johanna L’Heureux,Thomas von Erlach,Elena M Smekalova,Dominique Leboeuf,Kaitlyn Hess,Aaron Lopes,Jaimie Rogner,Joy Collins,Siddartha M Tamang,Keiko Ishida,Paul Chamberlain,DongSoo Yun,Abigail Lytton-Jean,Christian K Soule,Jaime H Cheah,Alison M Hayward,Robert Langer,Giovanni Traverso

Journal

Nature nanotechnology

Published Date

2021/6

Nanoformulations of therapeutic drugs are transforming our ability to effectively deliver and treat a myriad of conditions. Often, however, they are complex to produce and exhibit low drug loading, except for nanoparticles formed via co-assembly of drugs and small molecular dyes, which display drug-loading capacities of up to 95%. There is currently no understanding of which of the millions of small-molecule combinations can result in the formation of these nanoparticles. Here we report the integration of machine learning with high-throughput experimentation to enable the rapid and large-scale identification of such nanoformulations. We identified 100 self-assembling drug nanoparticles from 2.1 million pairings, each including one of 788 candidate drugs and one of 2,686 approved excipients. We further characterized two nanoparticles, sorafenib–glycyrrhizin and terbinafine–taurocholic acid both ex vivo and in vivo …

Implantable system for chronotherapy

Authors

Seung Ho Lee,Qianqian Wan,Adam Wentworth,Ian Ballinger,Keiko Ishida,Joy E Collins,Siddartha Tamang,Hen-Wei Huang,Canchen Li,Kaitlyn Hess,Aaron Lopes,Ameya R Kirtane,Jung Seung Lee,SeJun Lee,Wei Chen,Kaitlyn Wong,George Selsing,Hyunjoon Kim,Stephen T Buckley,Alison Hayward,Robert Langer,Giovanni Traverso

Journal

Science Advances

Published Date

2021/11/26

Diurnal variation in enzymes, hormones, and other biological mediators has long been recognized in mammalian physiology. Developments in pharmacobiology over the past few decades have shown that timing drug delivery can enhance drug efficacy. Here, we report the development of a battery-free, refillable, subcutaneous, and trocar-compatible implantable system that facilitates chronotherapy by enabling tight control over the timing of drug administration in response to external mechanical actuation. The external wearable system is coupled to a mobile app to facilitate control over dosing time. Using this system, we show the efficacy of bromocriptine on glycemic control in a diabetic rat model. We also demonstrate that antihypertensives can be delivered through this device, which could have clinical applications given the recognized diurnal variation of hypertension-related complications. We anticipate that …

Functionalized nanoparticles and methods of use thereof

Published Date

2021/4/6

A61K 31/765 424/78.31 5,792,742 A 2004/0057947 A1* 8/1998 Gold et al. 3/2004 Duettmann

Genotype-directed local delivery of targeted therapeutics

Published Date

2021/10/21

Provided herein are pharmaceutical compositions for local administration of metabolic inhibitors, methods of locally administering such compositions, and rapid diagnostic methods for identifying mutant allele during the course of a surgical procedure.

See List of Professors in Ameya Kirtane University(Harvard University)

Ameya Kirtane FAQs

What is Ameya Kirtane's h-index at Harvard University?

The h-index of Ameya Kirtane has been 21 since 2020 and 23 in total.

What are Ameya Kirtane's top articles?

The articles with the titles of

Screening oral drugs for their interactions with the intestinal transportome via porcine tissue explants and machine learning

Closed-loop automated drug infusion regulator: A clinically translatable, closed-loop drug delivery system for personalized drug dosing

A multifunctional decellularized gut suture platform

Challenges and opportunities in the development of mucosal mRNA vaccines

Oleogel and oleopaste compositions and uses thereof

Physical methods to overcome tissue barriers in vaccine delivery

Profiling of Circulating Tumor Cells for Screening of Selective Inhibitors of Tumor‐Initiating Stem‐Like Cells

Enzyme‐Triggered Intestine‐Specific Targeting Adhesive Platform for Universal Oral Drug Delivery (Adv. Healthcare Mater. 27/2023)

...

are the top articles of Ameya Kirtane at Harvard University.

What are Ameya Kirtane's research interests?

The research interests of Ameya Kirtane are: Drug delivery

What is Ameya Kirtane's total number of citations?

Ameya Kirtane has 2,076 citations in total.

What are the co-authors of Ameya Kirtane?

The co-authors of Ameya Kirtane are Robert Langer, Giovanni Traverso, Jayanth Panyam, Daniel Reker, Joy Collins, Siddartha Tamang.

    Co-Authors

    H-index: 319
    Robert Langer

    Robert Langer

    Massachusetts Institute of Technology

    H-index: 49
    Giovanni Traverso

    Giovanni Traverso

    Massachusetts Institute of Technology

    H-index: 47
    Jayanth Panyam

    Jayanth Panyam

    University of Minnesota-Twin Cities

    H-index: 26
    Daniel Reker

    Daniel Reker

    Duke University

    H-index: 20
    Joy Collins

    Joy Collins

    Harvard University

    H-index: 16
    Siddartha Tamang

    Siddartha Tamang

    Massachusetts Institute of Technology

    academic-engine

    Useful Links